Welcome to our dedicated page for FOXO Technologies news (Ticker: FOXO), a resource for investors and traders seeking the latest updates and insights on FOXO Technologies stock.
FOXO Technologies Inc. (symbol: FOXO) is leading the charge in transforming the global longevity and life insurance industries through cutting-edge epigenetic technology and AI-driven solutions. Founded under the names Yousurance and Life Epigenetics, the company has redefined how we understand and measure health and aging.
FOXO’s core business revolves around commercializing longevity science by utilizing epigenetic biomarkers to assess the biological age and health status of individuals. This revolutionary approach not only impacts life insurance underwriting protocols but also engages consumers directly through an advanced platform.
With a focus on DNA methylation, FOXO leverages supervised machine learning and artificial intelligence to pinpoint molecular signs of aging and health conditions. This enables more accurate risk assessment and personalized health insights, setting new standards in the insurance sector.
Recent achievements include groundbreaking advancements in epigenetic research and the integration of AI to enhance the precision of health evaluations. The company's current projects aim to further refine these technologies and expand their application range, ensuring they remain at the forefront of innovation in their field.
Financially, FOXO Technologies Inc. is committed to sustained growth and solidifying its market presence through strategic partnerships and continual investment in research and development. Their collaborations with leading scientific institutions and industry partners underscore their commitment to excellence and innovation.
Stay updated with the latest news and developments to see how FOXO Technologies Inc. continues to shape the future of longevity and health insurance.
FOXO Technologies Inc. (FOXO) has partnered with AmSuisse to enhance its insurance distribution through AmSuisse’s network of over 3,000 agents across 48 states. This collaboration aims to provide life insurance products accompanied by the FOXO Longevity Report, designed to improve client longevity and well-being. FOXO's Chief Distribution Officer, Jim Grauel, expressed excitement about reaching new markets, while AmSuisse’s CEO, Josh Hamann, highlighted the program's innovative, science-based approach to life insurance for independent agents.
FOXO Technologies Inc. (NYSEAM: FOXO) has filed its Form 10-Q for the third quarter ended September 30, 2022, after initially delaying it to review the accounting treatment of certain warrants and Series A Preferred Stock. The company confirmed that the accounting treatment was appropriate. Despite macro challenges, FOXO launched its first Longevity Report and an automated epigenetic testing system while integrating with two partners. The interim CEO expressed confidence in the company's direction, emphasizing innovation and adaptability to enhance user experience. FOXO has postponed its Q3 earnings call, planning instead for a Q4 update.
FOXO Technologies Inc. has announced significant changes in its executive leadership as of November 14, 2022. Jon Sabes has been terminated as CEO and Chairman of the Board. Tyler Danielson, previously Chief Technology Officer, has been appointed Interim CEO, while Bret Barnes takes over as Chairman. The company is in the process of searching for a permanent CEO. Additionally, Steve Sabes has been terminated as COO. FOXO plans to file for an extension with the SEC for its quarterly report for the period ending September 30, 2022.
FOXO Technologies Inc. (AMEX: FOXO) announced the resignation of Chief Product Officer Erin Sharoni effective November 9, 2022. The company expressed gratitude for her leadership, particularly regarding the FOXO Longevity Report. FOXO Technologies focuses on applying epigenetic science and AI to modernize the life insurance sector through innovative products and services aimed at improving underwriting processes and consumer value.
FOXO Technologies Inc. (AMEX: FOXO) has announced the postponement of its earnings conference call, with a subsequent press release to reveal the new date and time. This delay could indicate potential issues or uncertainty regarding the company's financial performance and outlook. FOXO operates at the intersection of technology and life insurance, focusing on epigenetic longevity science aimed at improving consumer underwriting processes through innovations like the FOXO Longevity Report™.
FOXO Technologies has announced a new managing general agency agreement between its subsidiary, FOXO LIFE, and Haven Life, a subsidiary of MassMutual. This strategic partnership aims to enhance FOXO LIFE's distribution of Haven Life insurance products through independent agents. This collaboration is set to expand FOXO LIFE's market reach, leveraging Haven Life's innovative digital purchasing experience in the life insurance sector. The announcement comes ahead of the NAILBA Annual Meeting, emphasizing FOXO's commitment to modernizing life insurance through technology.
FOXO Technologies Inc. (FOXO) announced it will report its financial results for the third quarter of 2022 on November 14, 2022, after market close. A conference call will be held at 3:15 p.m. Central time on the same day to discuss the results and recent business highlights. FOXO is focused on leveraging epigenetic technology to modernize the life insurance industry, utilizing AI to analyze DNA methylation for health biomarkers, enhancing the underwriting process, and improving consumer value prop through its FOXO Longevity Report.
FOXO Technologies Inc. (AMEX: FOXO) announced the recruitment of its first distribution partner, BGA Insurance, which represents over 4,000 independent agents in California. This partnership aims to promote longevity-focused life insurance products through FOXO LIFE. Additionally, James Grauel, Jr. has been appointed as Chief Distribution Officer to lead these efforts. The company will conduct agent recruitment events in Southern California starting October 19, 2022. The announcement follows FOXO's recent public trading debut with an enterprise value of approximately $369 million.
FOXO Technologies Inc. announced the completion of its business combination with Delwinds Insurance Acquisition Corp., with trading starting on the NYSE American under the symbol 'FOXO' from September 16, 2022. This strategic move aims to address key issues within the life insurance sector through epigenetic longevity science. FOXO's inaugural Managing General Agency relationship allows for marketing a range of life insurance products bundled with the FOXO Longevity Report™. The business combination received over 91% shareholder approval, underscoring strong investor confidence.
FAQ
What is the current stock price of FOXO Technologies (FOXO)?
What is the market cap of FOXO Technologies (FOXO)?
What does FOXO Technologies Inc. specialize in?
How does FOXO's technology work?
What are epigenetic biomarkers?
How is FOXO Technologies Inc. impacting the life insurance industry?
What are some recent achievements of FOXO Technologies Inc.?
What is FOXO Technologies Inc.’s approach to consumer engagement?
Who are FOXO Technologies Inc.'s partners?
What is DNA methylation?
Where is FOXO Technologies Inc. headquartered?
What is the future outlook for FOXO Technologies Inc.?
